Regulatory & Legal

A Canadian-made prostate treatment wins a major innovation award as new U.S. Medicare reimbursement positions it for explosive market growth.

A new plant-derived drug shows promise in preventing prostate cancer and improving cholesterol, but the company faces significant financial hurdles ahead.

The iconic brand is pivoting from its print legacy to a diversified lifestyle empire, and it has a new plan to convince investors it's the right move.

The casino giant posts a strong Q4 profit, reversing a prior year loss, as Macau's mass market boom and European expansion offset challenges in Manila.

Enhabit and Encompass Health collect millions in damages after a court found former execs committed 'egregious breaches of loyalty' to form a rival.

A new diagnostic tool for interstitial lung disease receives FDA Fast Track, promising earlier, more accurate detection of deadly lung inflammation.

As RSNs crumble, the St. Louis Cardinals and Gray Media launch a massive free TV package, bringing MLB and minor league games to fans across the Midwest.

SPJIMR's globally accredited PGPDM program welcomes a diverse new cohort, poised to tackle India's most pressing social and economic challenges.

A vibrant cultural showcase in Ethiopia highlights China's strategy to deepen Africa ties through soft power, moving beyond economics to win hearts and minds.

With over $10M in new funding, Berlin Heals is advancing a novel implant that uses a gentle electrical field to potentially reverse heart failure damage.

Aircraft leasing giant Avolon posts record profits, capitalizing on soaring travel demand and severe aircraft shortages plaguing global airlines.

The vaccine maker posts record 2025 earnings on mpox demand but signals a strategic shift, prioritizing its travel vaccine portfolio over new R&D.

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.

A potential first therapy for Charcot-Marie-Tooth disease heads to a major conference, showing promising functional gains despite missing its primary goal.

A new report shows 40% of ANZ firms never assess skin cancer risk, despite 84% seeing it as a duty of care, exposing a massive legal and health liability.

Proem Acquisition Corp I launches a $130M IPO, led by tech IPO guru Imran Khan. But can it succeed in a revived, yet risk-laden, SPAC landscape?

The satellite firm unveils a complex debt shuffle and $1B capital raise, fueling its network vision while sending its stock tumbling on dilution fears.

The health tech firm posts strong revenue and positive EBITDA, but SEC filings and a falling stock price reveal a more complex and challenging road ahead.

As BJ’s prepares to report Q4 results, investors are watching if a pizza relaunch and new efficiencies can overcome industry-wide cost pressures.

A bipartisan federal investigation will scrutinize university and government responses to a historic surge in antisemitism on college campuses since Oct. 7.